Back to Search
Start Over
Ready-to-use 177Lu-Rituximab injection for Non-Hodgkin’s Lymphoma: Formulation and preliminary clinical study.
- Source :
-
Journal of Radioanalytical & Nuclear Chemistry . Nov2018, Vol. 318 Issue 2, p849-856. 8p. 2 Color Photographs, 2 Charts, 3 Graphs. - Publication Year :
- 2018
-
Abstract
- This study was aimed at the preparation of 177Lu-CHX-A″-DTPA-Rituximab injection at the hospital pharmacy for non-Hodgkin lymphoma. Rituximab was conjugated with CHX-A″-DTPA-NCS and the CHX-A″-DTPA-Rituximab conjugate was radiolabeled with 177Lu in > 95% purity. The product exhibited excellent in vitro stability up to 5 days at 37 °C. In vitro cell binding studies in Raji cells confirmed the specificity of 177Lu-CHX-A″-DTPA-Rituximab to CD20 antigen. The radioimmunoconjugate exhibited predominantly hepatobiliary clearance and low bone uptake in Swiss mice. Preliminary clinical studies corroborated the usefulness of 177Lu-CHX-A″-DTPA-Rituximab for therapy of non-Hodgkin lymphoma. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 02365731
- Volume :
- 318
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Journal of Radioanalytical & Nuclear Chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 132400595
- Full Text :
- https://doi.org/10.1007/s10967-018-6042-7